COGT - Company ID 0001622229
The table below shows Cogent Biosciences, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $181.17M | $241.21M | $125.30M | $127.60M | $126.00M | $97.05M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $804.82M |
| $877.80M |
| $397.24M |
| $245.01M |
| $252.88M |
| $341.53M |
| Property, plant & equipment | $4.78M | $5.30M | $5.27M | $5.85M | $6.45M | $7.02M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $834.55M | $903.01M | $425.93M | $274.82M | $283.80M | $384.02M |
| Accounts payable | $7.49M | $13.74M | $16.03M | $16.63M | $14.15M | $15.06M |
| Total current liabilities | $59.30M | $57.98M | $62.25M | $58.42M | $49.32M | $53.05M |
| Long-term debt | $223.46M | $223.17M | $44.25M | $43.95M | - | - |
| Total liabilities | $302.16M | $295.31M | $123.47M | $119.78M | $64.80M | $69.36M |
| Retained earnings | -$1.38B | -$1.29B | -$1.09B | -$1.00B | -$931.47M | -$791.56M |
| Total equity | $532.39M | $607.69M | $302.46M | $155.04M | $219.00M | $314.66M |